Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lineage Cell Therapeutics (LCTX) FCF Margin (2016 - 2025)

Lineage Cell Therapeutics (LCTX) has 16 years of FCF Margin data on record, last reported at 79.86% in Q4 2025.

  • For Q4 2025, FCF Margin rose 16073.0% year-over-year to 79.86%; the TTM value through Dec 2025 reached 133.56%, up 11549.0%, while the annual FY2025 figure was 133.56%, 11549.0% up from the prior year.
  • FCF Margin reached 79.86% in Q4 2025 per LCTX's latest filing, up from 101.55% in the prior quarter.
  • Across five years, FCF Margin topped out at 417.38% in Q1 2022 and bottomed at 1901.53% in Q1 2021.
  • Average FCF Margin over 5 years is 324.58%, with a median of 240.59% recorded in 2024.
  • Peak YoY movement for FCF Margin: plummeted -92177bps in 2021, then soared 231891bps in 2022.
  • A 5-year view of FCF Margin shows it stood at 1901.53% in 2021, then soared by 78bps to 412.64% in 2022, then rose by 28bps to 298.78% in 2023, then increased by 19bps to 240.59% in 2024, then skyrocketed by 67bps to 79.86% in 2025.
  • Per Business Quant database, its latest 3 readings for FCF Margin were 79.86% in Q4 2025, 101.55% in Q3 2025, and 196.85% in Q2 2025.